4-ARYL OR HETEROARYL THIO-2-OXO-1-AZETIDINESULFONIC ACID SALTS AND PROCESS FOR THEIR PREPARATION

Abstract: Described are 4-aryl or heteroarylthio-2-oxo-1-azeti­ dinesulfonic acid salts having the formula wherein R is hydrogen or methoxy; R₁ is acyl; R₂ is aryl, 1H-tetrazol-5-yl, 1-alkyl-1H-tetrazol-5-yl, 1,3,4-thiadiazol-2-yl, 5-alkyl-1,3,4-thiadiazol-2-yl, 1,2,4-thia­ diazol-5-yl, 3-alkyl-1,2,4-thiadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 5-alkyl-1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-5-yl, 3-alkyl-1,2,4-­ oxadiazol-5-yl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-pyri­ midinyl, benzothiazol-2-yl, 4H-1,2,3-triazol-5-yl, 5-alkyl-4H-­ 1,2,3-triazol-5-yl, 1H-imidazol-2-yl, or 1-alkyl-1H-imidazol-­ 2-yl; and M⊕ Is hydrogen or a cation, with the proviso that if M⊕ is hydrogen the R₁ group contains a basic func­ tion; having anti bacterial activity. Described is also a process for their preparation.

Description: 4-ARYL OR HETEROARYL TEIO-2-OXO-1-AZETIDINESULFONIC ACID SALTS AND PROCESS FOR THEIR PREPARATION The present invention relates to 4-aryl or heteroarylthio-2-oxo-1-azetidine-sulfonic acid salts EMI1.1 In formula I, and throughout the specification, the symbols are as defined below. R is hydrogen or methoxy; R1 is alkyl; R2 is aryl, lH-tetrazol-5-yl, 1-alkyl- 1H-tetrazol-5-yl, 1,3,4-thiadiazol-2-yl, 5-alkyl-1,3,4-thiadiazol-2-yl, 1,2,4-thiadiazol5-yl, 3-alkyl-1,2,4-thiadiazol-5-yl, 1,3,4oxadiazol-2-yl, 5-alkyl-1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-5-yl, 3-alkyl-1,2,4-oxadiazol5-yl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-pyrimidinyl, benzothiazol-2-yl, 4H-1,2,3triazol-5-yl, 5-alkyl-4H-l,2 ,3-triazol-5-yl, lH-imidazol-2-yl, or l-alkyl-lH-imidazol-2 -yl; and Me is hydrogen or a cation. These compounds belong to the class of B-lactams. Listed below are definitions of various terms used to describe the ss-lactams of this invention. These definitions apply to the terms as they are used throughout the specification (unless they are otherwise limited in specific instances) either individually or as part of a larger group. The term "acyl" includes all organic radicals derived from an organic acid (i.e., a carboxylic acid) by removal of the hydroxyl group. Certain acyl groups are, or course, preferred but this preference should not be viewed as a limitation of the scope of this -invention. Exemplary acyl groups are those acyl groups which have been used in the past to acylate 8-lactam antibiotics including 6-aminopenicillanic acid and derivatives and 7-aminocephalosporanic acid and derivatives; see, for example, Cephalosporins and Penicillins, edited by Flynn, Academic Press (1972), German Offenlegungsschrift 2,716,677, published October 10, 1978, Belgian patent 867,994, published December 11, 1978, United States patent 4,152,432, issued May 1, 1979, United States patent 3,971,778, issued July 27, 1976, United States patent 4,172,199, issued October 23, 1979, and British patent 1,348,894, published March 27, 1974. The portions of these references describing various acyl groups are incorporated herein by reference. The following list of acyl groups is presented to further exemplify the term ''acyl'l; it should not be regarded as limiting that term. Exemplary acyl groups are: (a) Aliphatic groups having the formula EMI2.1 wherein Ra is alkyl; cycloalkyl; alkoxy; alkenyl; cycloalkenyl; cyclohexadienyl; or alkyl or alkenyl substituted with one or more halogen, cyano nitro, amino, mercapto, alkylthio, or cyanomethyl- thio groups. (b) Carbocyclic aromatic groups having the formula EMI3.1 EMI4.1 wherein n is 0, 1, 2 or 3; Rb, Rct and Rd each is independently hydrogen, halogen, hydroxyl, nitro, amino, cyano, -trifluoromethyl, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms or aminomethyl; and Re is amino, hydroxyl, a carboxyl salt, protected carboxyl, formyloxy, a sulfo salt, a sulfoamino- salt1 azido, halogen, hydrazino, alkylhydrazino, phenylhydrazino, or [(alkylthio)thioxomethyl]thio Preferred carbocyclic aromatic acyl groups include those having the formula EMI4.2 EMI5.1 (Re is preferably a carboxyl salt or sulfo salt) and EMI5.2 (Re is preferably a carboxyl salt or sulfo salt) (c) Heteroaromatic groups having the formula EMI5.3 wherein n is 0, 1, 2 or 3; Re is as defined above; and Rf is a substituted or unsubstituted 5-, 6- or 7-membered heterocyclic ring containing 1,2,3 or 4 (preferably 1 or 2).nitrogen, oxygen and sulfur atoms. Exemplary heterocyclic rings are thienyl, furyl, pyrrolyl, pyridinyl, pyrazolyl, pyrazinyl, thiazolyl, pyrimidinyl and tetrazolyl. Exemplary substituents are halogen, hydroxyl, nitro, amino, cyano, trifluoromethyl, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, or EMI6.1 Preferred heteroaromatic acyl groups include those groups of the above formulas wherein Rf is 2-amino-4-thiazolyl, 2-amino-5halo-4-thiazolyl, 4-aminopyrimidin-2-yl, 5-amino-1,2,4-thiadiazol-3-yl, 2-thienyl, 2-furanyl, or 6-aminopyridin-2-yl. (d) [[(4-Substituted-2,3-dioxo-f1-piper azinyl)carbonyl]amino]arylacetyl groups having the formula EMI6.2 wherein Rg is an aromatic group (including carbocyclic aromatics such as those of the formula EMI6.3 and-heteroaromatics as included within the definition of Rf); and Rh is alkyl, substituted alkyl (wherein the alkyl group is substituted with one or more halogen, cyano, nitro, amino or mercapto groups), arylmethyleneamino (i.e., -N=CH-R9 wherein R9 is as defined above), arylcarbonylamino EMI7.1 wherein R g is as defined above) or alkylcarbonylamino. Preferred [[(4-substituted-2,3-dioxo-1 piperazinyl)carbonyl] amino] arylacetyl groups include those wherein E is ethyl, phenylmethyleneamino or 2-furylmethyleneamino. (e) (Substituted oxyimino)arylacetyl groups having the formula EMI7.2 wherein Rg is as defined above and R. is hydrogen, alkyl, cycloalkyl, alkylaminocarbonyl, arylaminocarbonyl (i.e., EMI7.3 wherein R9 is as defined above) or substituted alkyl (wherein the alkyl group is substituted with 1 or more halogen, cyano, nitro, amino, mercapto, alkylthio, aromatic group (as defined by R ), carboxyl g (including salts thereof), amido, alkoxycarbonyl, phenylmethoxycarbonyl, diphenylmethoxycarbonyl, hydroxyalkoxyphosphinyl, dihydroxyphosphinyl, hydroxy (phenylmethoxy) phosphinyl, or dialkoxy phosphinyl substituents). Preferred (substituted oxyimino)arylacetyl groups include those wherein R is 2-amino-4 g thiazolyl. Also preferred are those groups wherein R. is methyl, ethyl, carboxymethyl, 1. l-carboxy-l-methylethyl or 2,2,2-trifluoroethyl. (f) fAcylamino)arylacetyl groups having the formula EMI8.1 wherein R9 is as defined above and Rj is EMI8.2 amino, alkylamino, (cyanoalkyl)amino, amido, alkylamido, (cyanoalkyl)amido, EMI8.3 EMI8.4 Preferred (acylamino) arylacetyl groups of the above formula include those groups wherein R. is amino or amido. 'Also preferred are 3 those groups wherein R is phenyl or 2-thienyl. (g) [[(3-Substituted-2-oxo-1-imidazolidinyl]carbonyl]amino]arylacetyl groups having the formula EMI9.1 wherein Rg is as defined above and Rk is hydrogen, alkylsulfonyl, arylmethyleneamino (i.e., N=CHRg wherein Rg is as defined above), EMI9.2 (wherein Rm is hydrogen, alkyl or halogen substituted alkyl), aromatic group (as defined by Rg above), alkyl or substituted alkyl (wherein the alkyl group is substituted with one or more halogen, cyano, nitro, amino or mercapto groups). Preferred [[3-substituted-2-oxo-1-imidazoli- dinyl]carbonyl]aminoiarylacetyl groups of the above formula include those wherein R is phenyl or 2-thienyl. Also preferred are those groups wherein Rk is hydrogen, methylsulfonyl, phenyl me thy leneamino or 2-furylmethyleneamino. The terms "alkyl" and "alkoxy" refer to both straight and branched chain groups. Those groups having 1 to 10 carbon atoms are preferred. The terms "alkanoyl" and "alkenyl" refer to both straight and branched chain groups. Those groups having 2 to -10 carbon atoms are preferred. The terms "cycloalkyl" and "cycloalkenyl" refer to groups having 3,4,5,6 or 7 carbon atoms. The term "cation", as used throughout the specification, refers to any positively charged atom or group of atoms. The "-SO3-M+" substituent on the nitrogen atom of the ss-lactams of this invention encompasses.all sulfonic acid salts. Pharmaceutically acceptable salts are, of course, preferred, although other salts are also useful in purifying the products of this invention or as intermediates for the-preparation of pharmaceutically acceptable salts. The cationic portion of the sulfonic acid salts of this invention can be obtained from either organic or inorganic bases. Such cationic portion includes, but is not limited to, the following ions: ammonium; substituted ammonium, such as alkylammon ium (e.g., tetra-n-butylammonium, referred to hereinafter as tetrabutylammonium); alkali metal, such as lithium, sodium and potassium; alkaline earth metal, such as calcium and magnesium; pyridinium; dicyclohexylammonium; hydrabaminium; benzathinium; N-methyl-D-glucaminium. The term naryl" refers to phenyl and phenyl substituted with 1, 2 or 3 amino (-NH2), halogen, hydroxyl, trifluoromethyl, alkyl (of 1 to 4 carbon atoms) or alkoxy (of 1 to 4 carbon atoms) groups. As set forth in formula I, and in the definitions following formula I, Me can be hydrogen. Such compounds are often referred 'to in the art as "inner salts" by virtue of a positive and negative charge in the molecule. This invention is directed to those B-lactams which have been described above, wherein the stereochemistry at the chiral center in the 3-position of the ss-lactam nucleus is the same as the configuration at the carbon atom in the 6-position of naturally occurring penicillins (e.g., penicillin G) and as the configuration at the carbon atom in the 7-position of naturally occurring cephamycins (e.g., cephamycin C) The B-lactams of formula I have activity against a range of gram-negative and gram-positive organisms. The compounds of this invention can be used as agents to combat bacterial infections (including urinary tract infections and respiratory infections) in mammalian species, such as domesticated animals (e.g., dogs, cats, cows, horses, and the like) and humans. For combating bacterial infections in mammals a compound of this invention can be administered to a mammal in need thereof in an amount of about 1.4 mg/kg/day to about 350 mg/kg/day, preferably about 14 mg/kg/day to about 100 mg/kg/day. All modes of administration which have been used in the past to deliver penicillins and cephalosporins to the site of the infection are also contemplated for use with the novel ss-lactams of this invention. Such methods of administration include oral1 intravenous, intramuscular, and as a suppository. The compoundsof formula can be prepared from an azetidine having the formula EMI12.1 wherein A1 is a nitrogen protecting group, e.g., triphenylmethyl, and A2 is an alkyl or aryl group. Reaction of an azetidine of formula IIa or IIb with a thiolate having the formula III #S-R2 yields a mixture of diastereomers of the formulas EMI13.1 and Separation of the above diastereomers can be accomplished using conventional chromatographic or fractional crystallization techniques. The addition of a sulfo tS03) group to the 1position of a compound of formula IVa or IVb or a corresponding compound wherein A1 has been replaced by the R1-group yields the corresponding compound having the formula EMI13.2 Introduction of the sulfo substituent can be accomplished by reacting a compound of formula IVa or IVb with a complex of pyridine and sulfur trioxide. The reaction can be run in an organic. solvent or in a mixture of organic solvents, preferably a mixture of a polar solvent such as dimethylformamide and a halogenated hydrocarbon such as dichloromethane. This reaction yields a compound of formula V wherein Me is pyridinium ion. Instead of using a pre-formed complex of pyridine and sulfur trioxide, the complex can be formed in situ, e.g., using chlorosulfonyltrimethylsilyl ester and pyridine as reagents. Alternatively, a complex of dimethylformamide-sulfur trioxide, 2-picoline-sulfur trioxide or 2,6-lutidine sulfur trioxide can be used. Using conventional techniques Ce.g., ion-exchange resins,- crystallization, or ion-pair extraction) the pyridinium salt formed by the above procedure can be converted to other salts. These techniques can also be used to convert the products of formula I, or any of the intermediates described herein, to other salts. A second method for introducing the sulfo group to the l-position of an azetidine of formula IVa or IVb comprises first silylating the compound and then subjecting the silated compound to a silyl interchange reaction. Exemplary silylating agents are monosilyltrifluoroacetamide, trimethylsilylchloride/triethylamine, and bis-trimethylsilyltrifluoroacetamide, and an exemplary reagent useful for the silyl interchange reaction is trimethylsilyl chlorosulfonate. Deprotection of an azetidine of formula V yields a zwitterion having the formula EMI15.1 The deprotection techniques used are conventional, and will depend on the particular protecting group CA1) present. Treatment with acid (e.g., formic acid or trifluoroacetic acid) cleaves a triphenylmethyl or a t-butoxyca-rbonyl protecting group. A benzyloxycarbonylamino protecting group can be cleaved by treatment with trimethyisilyl iodide. Treatment with phosgene or phosphorous pentachloride cleaves an amide protecting group. The zwitterions of formula VI are novel intermediates, and as such, constitute an integral part of this invention. Conventional acylation techniques can be used to prepare the products of formula I wherein R is hydrogen2 from a zwitterion of formula YI. Exemplary acylation techniques include reaction with a carboxylic acid (Ri-OH), or corresponding carboxylic acid halide or carboxylic acid anhydride. The reaction with a carboxylic acid proceeds most readily in the presence of a carbodiimide and a substance capable of forming an active ester in situ such as N-hydroxybenzotriazole. In those instances wherein the acyl group (R1) contains reactive functionality (such as amino or carboxyl groups) it may be necessary to first protect those functional groups, then carry out the acylation reaction, and finally deprotect the resulting product. Variations of the above described synthetic route (some of which are described in the examples presented below) will be apparent to the practitioner of this invention. For example, a compound of formula IVa or IVb can be deprotected and then protected with a different amino protecting group before proceeding with theremaining synthetic procedure. The ss-lactams of formula I wherein R is methoxy can be prepared from the corresponding compound of formula I wherein R is hydrogen. Halogenation of the amide nitrogen of a non-methoxylated compound of formula I yields, in situ, an intermediate having the formula EMI16.1 Reaction of an intermediate of formula VII with a methoxylating agent, e.g., an alkali metal methoxide yields a product of formula I wherein R is methoxy. The reaction can be run in an organic solvent, e;g., a polar orgainc solvent such as dimethylformamide, at a reduced temperature. An alternative synthesis for preparing the compounds of formula I wherein R is methoxy comprises first alkoxylating a compound of formula IVa or IVb wherein A1NH is a carbamate (e.g., A1 is benzyloxycarbonyl) and then introducing a sulfo group in the 1-position of the resulting compound. Deprotection and acylation, using the procedures described above, yields the products of formula I wherein R is methoxy. The following examples are specific embodiments of this invention. Example 1 (3R-trans)-3-Amino-4-[(1-methyl-1h-tetrazol5-yl)thio]-2-oxo-1-azetidinesulfonic acid, inner salt Method I A) (3R-cis)-4-[(1-methyl-1H-tetrazol-5-yl)thio]3-[(triphenylmethyl)amino]-2-azetidinone and (3R-trans)-4-[(1-methyl-1H-tetrazol-5-yl)thio]3-[(triphenylmethyl)amino]-2-azetidinone (cis)-[2-Oxo-3-[(triphenylmethyl)amino]4-azetidinyl]methyl sulfone (2.04 g) is dissolved in 30 ml of methanol, 0.2 g of 1,4,7,10,13,16-hexaoxacyclooctadecane is added, and with stirring, a solution of 0.8 g of the sodium- salt of 5-mercapto-1-methyl- 1H-tetrazole in 20 ml of methanol is added dropwise at a temperature of 60 C. Stirring is continued for 3 hours. The reaction solution is poured into 200 ml of ice-water yielding 2.6 g of crystalline crude product. Chromatography on silica, eluting with dichloromethane-ethyl acetate (9:1), yields 0.7 g of the cis isomer, 0.9 g of the trans isomer, and 0.4 g of a mixture of isomers. B) (3R-trans)-4-[(1-methyl-1H-tetrazol-5-yl)thio] 2-oxo-3- [ (triphenylmethyl) amino) -1-azetidine- sulfonic-acid, tetrabutylammonium salt (3R-trans)-4-[(1-methyl-1H-tetrazol-5 l)thiol-3-[(triphenylmethyljamino]-2-azetidinone (4.25 g) and 3.2 g of a complex of pyridinesulfur trioxide-are dissolved in dimethylformamide and stirred for 48 hours at room temperature. The solution is poured into 200 ml of ice-water, 3.26 g of tetrabutylammonium hydrogen sulfate are added and the pH is adjusted to pH 5.5 with 1N potassium hydroxide. Ion pair extraction with dichloromethane yields 6.2 g of crude title compound as an oil. C) (3R-trans) -3-Amino-4-[ (l-methyl-lH-tetrazol- 5-yl)thio]-2-oxo-1-azetidinesulfonic acid, inner salt (3R-trans) -4 - [(1-methyl -lH-tetrazol-5 - yl)thio]-2-oxo-3-[(triphenylmethyl)amino]-1azetidinesulfonic acid, tetrabutylammonium salt (6 g) are stirred in 20 ml of formic acid and dichloromethane (9:1) for about 1 hour. The solution is poured into 200 ml of ether, precipitating the title compound as a powder, melting point 1120C, dec. Method II A) (3R-trans)-3-Amino-4-[(1-methyl-1H-tetrazol5-yl)thio]-2-azetidinone, p-toluenesulfonate (3R-trans)-4-[(1-Methyl-1H-tetrazol-5-yl)thio]-3-[(triphenylmethyl)amino]-2-azetidinone (3.5g; see method -I, part A) and 1.5g of p-toluenesulfonic acid are stirred in 20 ml of dichloromethane at 0 C for 90 minutes. Ether is adding, causing the title compound to precipitate; melting point 137 C, dec. B) (3R-trans)-4-[(1-methyl-1H-tetrazol-5-yl)thio]-3-[[(1,1-dimethylethyl)carbonyl]amino]2-azetidinone (3R-trans)-3-Amino-4-[(1-methyl-1H-tetrazol5-yl)thio]-2-azetidinone, p-toluenesulfonate (2.0g) and 1.0gof triethylamine are dissolved in 15 ml-of t-butanol and 1.4g of di-t-butylpyrocarbonate in tetrahydrofuran are added. After stirring for 8 hours at 5 C, the solvent is distilled off and the residue is dissolved in 50 ml of ethyl acetate. E-xtraction with aqueous citric acid and water yields the title compound from the organic phase; melting point 105 C, dec. C) (3R-trans)-3-Amino-4-[(1-methyl-1H-tetrazol5-yl)thio]-2-oxo-1-azetidinesulfonic acid, inner salt (3R-trans) -4-[ (l-methyl-lH-tetrazol-5-- yl)thio]-3-r[(l,l-dLmethylethyl)carbonyl]- amino]-2-azetidinone (300 mg) and 320 mg of a complex of pyridine and sulfur trioxide are dissolved in 10 mi of dimethylformamide and stirred for 12 hours at 500C. The solution is poured into 80 ml of ice-water, 370 mg of tetrabutylammonium hydrogen sulfate is added and the pH is adjusted to 5.5 with IN potassium hydroxide. Extraction with dichloromethane yields an oily residue from the organic phase. This is stirred for 1 hour in 10 ml of formic acid/dichloromethane (91) and poured into 40 ml of ether, yielding 110 mg of the title compound. Example 2 [(3R-trans) (Z)]-3-[[[(2-Amino-4-thiazolyl)methoxy imino]acetylJamino]-4- r (l-methyl-lH-tetrazol- 5-yl)thio] -2-oxo-1-azetidinesulfonic acid, potassium salt (3R-trans)-3-Amino-4-[(l-methyl-1H- tetrazol-5-yl)thio]-2-oxo-1-azetidinesulfonic acid, inner salt (268.2 mg; see example 1), 202 mg of (Z)-2-amino-a-(methoxyimino)-4- thiazoleacetic acid, 101 mg of triethylamine and 175 mg of N-hydroxybenzotriaz6le are dissolved in 10 ml of dimethylformamide. At 0 C a solution of 206 my of dicyclohexyl carbodiimide in 3 ml-of tetrahydrofuran is added dropwise. After stirring for 12 hours at room temperature, the solvent is distilled off and the residue is dissolved in-acetone. Filtration, followed by the addition of 340 mg of potassium perfluorobutane sulfonate to the filtrate yields 0.3 g of crude product. Column chromatography on HP20 using water/acetone (9:1) as eluent yields the title compound, melting point 176-180 C. Example 3 [(3R-trans) (R*)]-3-[[[[(4-ethyl-2,3-dioxo-1piperazinyl)carbonyl]amino]phenylacetyl]amino]2-oxo-4-[(1-methyl-1H-tetrazol-5-yl)thio]-1azetidinesulfonic acid, potassium salt Following the procedure of example 2, but substituting (R)-&alpha;-[[(4-ethyl-2,3-dioxo- 1-piperazinyl)carbonyl]amino]benzeneacetic acid for (Z) -2-amino-a- (methoxyimino) -4- thiazoleacetic acid, yields the title-compound, melting point 184 0C. Example 4 (3R-trans)-4-[(1-Methyl-1h-tetrazol-5-yl)thio]2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-1azetidinesulfonic acid, potassium salt A) (3R-trans) -4-[ (l-Methyl-1H-tetrazol-5-yl)- thio]-3-[[(phenylmethoxy)carbonyl]amino]-2azetidinone (3R-trans)-4-(Acetyloxy)-3-[[(phenyl- methoxy)carbonyl]amino] -2-azetidinone (1.4 g) is dissolved in 20 ml of dry dimethylformamide at a temperature of 50 C.The sodium salt of 5-mercapto-l-methyl-lH-tetrazole (08 g) is added to the solution and the resulting mixture is stirred for 20 minutes Water (300 ml) is added and the mixture is filtered yielding the title compound. Recrystallization from ethyl acetate yields 1.2 g of the title compound, melting point 194 C, dec. B) (3R-trans)-4- [ (l-Methyl-lH-tetrazol-5-yl)- thio]-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-1azetidinesulfonic acid, potassium salt (3R-trans)-4-[(1-Methyl-1H-tetrazol-4-yl)thio]-3-[[(phenylmethoxy)carbonyl]amino-2azetidinone (1.7 g) is dissolved in 30 ml of ace+onitrile (dried) and 3 ml of monosilyltrifluoroacetamide is added; the solution is mashtained at 500C for 2 hours. The mixture is evaporated to remove excess monosilyltrifluoroacetamide. The remaining oil is dissolved in 15 ml of acetonitrile, cooled to -100C and 6 mmol of trimethylsilyl chlorosulfonate is added; stirring is continued for 30 minutes. A 2N solution (5 ml) of potassium 2-ethylhexanoate in n-butanol is added and the title compound precipitates. The precipitate is filtered off, dissolved in 10 ml of dibasic potassium phosphate/potassium hydroxide buffer (pH 5.0) and chromatographed on HP20 resin, eluting with water. After freeze-drying, 0.9 g of the title compound is obtained; melting point 143 C, dec. Examples 5-14 Following the procedures of examples 1 (method I) and 2, but substituting the sodium salt of the compound listed in column I for the sodium salt of 5-mercapto-1-methyl- lH-tetrazole and the compound listed in column II for (Z) -2-amino-a- (methoxyimino) - 4-thiazoleacetic acid, yields the compound listed in column III. Examples 11 and 12 require a deprotection step at the end of the reaction. Deprotection is accomplished in examples 11 and 12 by treatment of the protected compound with trifluoroacetic acid and anisole at -15 0C. EMI25.1 <SEP> Column <SEP> I <SEP> Column <SEP> II <SEP> Column <SEP> III <tb> 5) <SEP> # <SEP> # <SEP> # <tb> 6) <SEP> # <SEP> # <SEP> # <tb> 7) <SEP> # <SEP> # <SEP> # <tb> 8) <SEP> # <SEP> # <SEP> # <tb> EMI26.1 <SEP> Column <SEP> I <SEP> Column <SEP> II <SEP> Column <SEP> III <tb> 9) <SEP> # <SEP> # <SEP> # <tb> 10) <SEP> # <SEP> # <SEP> # <tb> 11) <SEP> # <SEP> # <SEP> # <tb> 12) <SEP> # <SEP> # <SEP> # <tb> EMI27.1 <SEP> Column <SEP> I <SEP> Column <SEP> II <SEP> Column <SEP> III <tb> 13) <SEP> # <SEP> # <SEP> # <tb> 14) <SEP> # <SEP> # <SEP> # <tb>

Claims: CLAIMS: 1. 4-Aryl or heteroarylthio-2-oxo-1-azetidine- sulfonic acid salts havana the formula EMI28.1 wherein R is hydrogen or methoxy; R1 is acyl; R2 is aryl, lH-tetrazol-5-ylr l-alkyl1H-tetrazol-5-yl, 1,3,4-thiadiazol-2-yl, 5-alkyl-1,3,4-thiadiazol-2-yl, 1,2,4-thiadiazol5-yl, 3-alkyl-1,2,4-thiadiazol-5-yl, 1,3,4- oxadiazol-2-yl, 5-alkyl-1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-5-yl, 3-alkyl-1,2,4-oxadiazol5-yl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-pyrimidinyl, benzothiazol-2-yl, 4H-l, 2,3- triazol-5-yl, 5-alkyl-4H-1,2,3-triazol-5-yl, 1H-imidazol-2-yl, or 1-alkyl-1H-imidazol-2-yl; and M+ is hydrogen or a cation. 2. A compound in accordance with claim 1 having the formula EMI28.2 3. A compound in accordance with claim 1 having the formula EMI29.1 4.. The compound in accordance with claim 1 [(3R-trans) (Z)]-[[[(2-amino-4-thiazolyl)methoxyimino]acetylamino]-4-[(1-methyl-1H-tetrazol 5-yl)thio]-2-oxo-l-azetidinesulfonic acid, potassium salt. 5. The compound in accordance with claim 1 [(3R-trans) (R*)]-3-[[[[(4-ethyl-2,3-dioxo-1 piperazinyl)carbonyl]aminoAphenylacetyl]amino]- 2-oxo-4-[(1-methyl-1H-tetrazol-5-yl)thio]-1azetidinesulfonic acid, potassium salt. 6. The compound in accordance with claim 1 (3R-trans)-4-[(1-methyl-1h-tetrazol-5-yl)thio]2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-1azetidinesulfonic acid, potassium salt. 7. A compdund having the formula EMI29.2 wherein R2 is aryl, lH-tetrazol-5-yl, 1alkyl 1H-tetrazol-5-yl, 1,3,4-thiadiazol-2-yl, 5-alkyl-l ,3,4-thiadiazol-2-yl, 1,2,4-thiadiazol5-yl, 3-alkyl-1,2,4-thiadiazol-5-yl, 1,3,4 oxadiazol-2-yl, 5-alkyl-1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-5-yl 3-alkyl-1,2,4-oxadiazol 5-yl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-pyrimidinyl, benzothiazol-2-yl, 4H-1,2,3- triazol-5-yl, 5-alkyl-4H-1,2,3-triazol-5-yl, 1H-imidazol-2-yl, or 1-alkyl-1H-imidazol-2-yl. 8. A compound in accordance with claim 7 having the formula EMI30.1 9. A compound in accordance with claim 7 having the formula EMI30.2 10. A process for preparing a compound of claim 1 characterized by adding a sulfo group (SO3#) to the 1-position of a compound of the formula EMI30.3 wherein A1 is a nitrogen protecting group, according to conventional methods. 11. Pharmaceutical compositions containing a compound of claim 1 to 9.

Inventors: BREUER, HERMANN, DENZEL, THEODOR, TREUNER, UWE D.
Applicants: E.R. SQUIBB & SONS, INC.
Application year: 1982
Main classification: C07D417
IPC codes: C07D409, C07D205, A61K31, C07D403, C07D413, A61P31, C07D417